

Eric S Lipp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4489200/eric-s-lipp-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111
papers

9,607
citations

38
h-index

98
g-index

116
ext. papers

12,277
ext. citations

5.1
avg. IF

4.95
L-index

#	Paper	IF	Citations
111	Availability and role of clinical pharmacists in ambulatory neuro-oncology.. <i>Neuro-Oncology Practice</i> , 2022 , 9, 18-23	2.2	
110	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.. <i>Supportive Care in Cancer</i> , 2022 , 30, 3463	3.9	
109	QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS. <i>Neuro-Oncology</i> , 2021 , 23, vi184-vi185	1	
108	QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE. <i>Neuro-Oncology</i> , 2021 , 23, vi189-vi189	1	
107	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9521-9521	2.2	
106	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021 , 12, 352	17.4	31
105	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021 , 8, 299-309	2.2	1
104	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 631618	5.3	
103	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. <i>CNS Oncology</i> , 2021 , 10, CNS77	4	0
102	BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM. <i>Neuro-Oncology</i> , 2021 , 23, vi14-vi15	1	
101	IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020 , 22, iii365-iii365	1	78
100	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 477-483	4.8	3
99	NCOG-38. CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS. <i>Neuro-Oncology</i> , 2020 , 22, ii137-ii137	1	
98	QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS. <i>Neuro-Oncology</i> , 2020 , 22, ii179-ii179	1	
97	NCOG-23. PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2020 , 22, ii134-ii134	1	
96	COVID-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING. <i>Neuro-Oncology</i> , 2020 , 22, ii26-ii26	1	
95	QOLP-05. OLANZAPINE FOR REFRACTORY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020 , 22, ii175-ii175	1	

94	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2020 , 22, ii38-ii38	1	2
93	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2566-2566	2.2	2
92	CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. <i>Neuro-Oncology</i> , 2020 , 22, ii37-ii37	1	2
91	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020 , 139, 277-286	14.3	12
90	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. <i>Clinical Cancer Research</i> , 2020 , 26, 5809-5813	12.9	17
89	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020 , 28, 2229-2238	3.9	5
88	First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, E106	4	2
87	Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. <i>Health Science Reports</i> , 2019 , 2, e114	2.2	7
86	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019 , 36, 43-48	3.5	2
85	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2060-2060	2.2	1
84	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13526-e13526	2.2	4
83	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019 , 21, vi6-vi6	1	1
82	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019 , 21, vi8-vi8	1	78
81	QOLP-18. A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019 , 21, vi201-vi201	1	2
80	QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019 , 21, vi204-vi204	1	1
79	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz036	0.9	2
78	HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS. <i>Neuro-Oncology</i> , 2019 , 21, vi116-vi116	1	78
77	INNV-18. THE AVAILABILITY AND ROLE OF CLINICAL PHARMACISTS IN THE AMBULATORY NEURO-ONCOLOGY SETTING: AN INTERNATIONAL SURVEY. <i>Neuro-Oncology</i> , 2019 , 21, vi134-vi134	1	78

76	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019 , 78, 57-64	3.1	4
75	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018 , 23, 889-e98	5.7	17
74	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e12	10.2	133
73	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018 , 23, 282-296.e4	10.6	188
72	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
71	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018 , 23, 297-312.e12	10.6	147
70	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. <i>Oncologist</i> , 2018 , 23, 157-e21	5.7	33
69	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 349-356	4.8	37
68	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
67	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	10.3	377
66	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018 , 136, 227-237	14.3	52
65	QOLP-17. REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi218-vi218	1	1
64	GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi112-vi112	1	78
63	HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS. <i>Neuro-Oncology</i> , 2018 , 20, vi117-vi117	1	78
62	RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS. <i>Neuro-Oncology</i> , 2018 , 20, vi239-vi239	1	78
61	ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi17-vi17	1	1
60	QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi217	1	78
59	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2018 , 20, vi9-vi9	1	1

58	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018 , 20, vi7-vi7	1	78
57	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018 , 34, 430-442	3-7	4
56	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018 , 34, 472-485	3-7	1
55	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi102-vi103	1	78
54	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
53	Adjunctive perampanel for glioma-associated epilepsy. <i>Epilepsy & Behavior Case Reports</i> , 2018 , 10, 114-117	11	16
52	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018 , 20, i93-i93	1	2
51	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018 , 9, 2087	17.4	78
50	PALL-02. PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology</i> , 2017 , 19, vi168-vi168	1	78
49	QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2017 , 19, vi206-vi206	1	78
48	QLIF-34. PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW GRADE GLIOMAS (LGG). <i>Neuro-Oncology</i> , 2017 , 19, vi208-vi209	1	78
47	RARE-36. PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. <i>Neuro-Oncology</i> , 2017 , 19, vi217-vi217	1	78
46	Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 1697-1704	5	26
45	A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. <i>Journal of Neuro-Oncology</i> , 2017 , 134, 363-369	4.8	15
44	Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. <i>Neuro-Oncology</i> , 2017 , 19, 31-42	1	38
43	PALL-10. INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2017 , 19, vi170-vi170	1	78
42	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13532-e13532	2.2	2
41	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13533-e13533	2.2	

40	Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21636-e21636	2.2	
39	ATIM-18. PHASE II DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2016 , 18, vi21-vi22	1	1
38	NCOG-12. NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS. <i>Neuro-Oncology</i> , 2016 , 18, vi122-vi122	1	
37	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
36	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , 2016 , 17, 484-495	21.7	187
35	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2061-2061	2.2	11
34	Baseline cognitive function to predict survival in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10125-10125	2.2	
33	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015 , 372, 2481-98	59.2	1828
32	Consultative issues in surgical neuropathology: a retrospective review of the rationale for submitting cases for expert review. <i>American Journal of Clinical Pathology</i> , 2015 , 143, 807-11	1.9	3
31	Prognostic marker analysis in pediatric intracranial ependymomas. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 255-61	4.8	9
30	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015 , 133, 730-8	6	10
29	QOL-19 PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN. <i>Neuro-Oncology</i> , 2015 , 17, v192.1-v192.7 ⁸		
28	QOL-20 LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY. <i>Neuro-Oncology</i> , 2015 , 17, v192.2-v192.7 ⁸		
27	ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2015 , 17, v1.1-v1	1	1
26	QOL-21 DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. <i>Neuro-Oncology</i> , 2015 , 17, v192.3-v192	1	78
25	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015 , 20, 727-8	5.7	24
24	Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2034-2034	2.2	4
23	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2068-2068	2.2	7

22	Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2067-2067	2.2	
21	Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13004-e13004	2.2	
20	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9553-9553	2.2	1
19	Secondary cancers in long-term survivors of primary glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20616-e20616	2.2	
18	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014 , 5, 1452-7	3.3	59
17	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014 , 5, 1515-25	3.3	187
16	Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2082-2082	2.2	
15	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
14	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , 2013 , 14, 1200-7	21.7	226
13	Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. <i>Cancer Medicine</i> , 2013 , 2, 185-95	4.8	32
12	Phase II study of Gleevec plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 409-15	4.8	62
11	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 213-21	4.8	21
10	Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 23-34	2.1	27
9	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012 , 3, 709-22	3.3	439
8	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012 , 118, 4759-67	6.4	26
7	Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. <i>British Journal of Cancer</i> , 2012 , 107, 1481-7	8.7	73
6	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2027-2027	2.2	1
5	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2074-2074	2.2	1

4	Association between body mass index and mortality in patients with glioblastoma mutliforme. <i>Cancer Causes and Control</i> , 2010 , 21, 2195-201	2.8	21
3	MRP3: a molecular target for human glioblastoma multiforme immunotherapy. <i>BMC Cancer</i> , 2010 , 10, 468	4.8	35
2	Family Appraisal of Caregiving in a Brain Cancer Model. <i>Journal of Hospice and Palliative Nursing</i> , 2009 , 11, 60-66	2.2	8
1	Distress persists in long-term brain tumor survivors with glioblastoma multiforme. <i>Journal of Cancer Survivorship</i> , 2008 , 2, 269-74	5.1	22